{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:38:32Z","timestamp":1789501112620,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 81272341"],"award-info":[{"award-number":["Grant No. 81272341"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00262-017-1989-8","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T07:38:24Z","timestamp":1493105904000},"page":"1153-1162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series"],"prefix":"10.1007","volume":"66","author":[{"given":"Xizhi","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"1989_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","volume":"16","author":"C Garbe","year":"2011","unstructured":"Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16:5\u201324","journal-title":"Oncologist"},{"key":"1989_CR2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumabin unresectable or metastatic melanoma. J ClinOncol 33:1889\u20131894","journal-title":"J ClinOncol"},{"key":"1989_CR3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134\u2013144","journal-title":"N Engl J Med"},{"key":"1989_CR4","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J ClinOncol 32:1020\u20131030","journal-title":"J ClinOncol"},{"key":"1989_CR5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122\u2013133","journal-title":"N Engl J Med"},{"key":"1989_CR6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumaband ipilimumabor monotherapy in untreated melanoma. N Engl J Med 373:23\u201334","journal-title":"N Engl J Med"},{"issue":"suppl 15","key":"1989_CR7","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1200\/JCO.2016.34.15_suppl.9506","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV, Atkinson V, Cebon JS et al (2016) Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. J ClinOncol 34(suppl 15):9506 (ASCO Annual Meeting abstract)","journal-title":"J ClinOncol"},{"key":"1989_CR8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-11-85","volume":"11","author":"Z Chi","year":"2011","unstructured":"Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J (2011) Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11:85","journal-title":"BMC Cancer"},{"key":"1989_CR9","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135\u20132147","journal-title":"N Engl J Med"},{"key":"1989_CR10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/path.4204","volume":"230","author":"SJ Furney","year":"2013","unstructured":"Furney SJ, Turajlic S, Stamp G et al (2013) Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol 230:261\u2013269","journal-title":"J Pathol"},{"key":"1989_CR11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/pcmr.12279","volume":"27","author":"SJ Furney","year":"2014","unstructured":"Furney SJ, Turajlic S, Stamp G et al (2014) The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell. Melanoma Res 27:835\u2013838","journal-title":"Melanoma Res"},{"key":"1989_CR12","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","volume":"22","author":"AN Shoushtari","year":"2016","unstructured":"Shoushtari AN, Munhoz RR, Kuk D et al (2016) The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 22:3354\u20133362","journal-title":"Cancer"},{"key":"1989_CR13","doi-asserted-by":"publisher","first-page":"e0131403","DOI":"10.1371\/journal.pone.0131403","volume":"10","author":"P Wu","year":"2015","unstructured":"Wu P, Wu D, Li L, Chai Y, Huang J (2015) PD-L1 and survival in solid tumors: a meta-analysis. PLoS One 10:e0131403. doi: 10.1371\/journal.pone.0131403","journal-title":"PLoS One"},{"key":"1989_CR14","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908\u2013918","journal-title":"Lancet Oncol"},{"key":"1989_CR15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109\u20131117","journal-title":"Lancet"},{"key":"1989_CR16","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","volume":"34","author":"AI Daud","year":"2016","unstructured":"Daud AI, Wolchok JD, Robert C et al (2016) Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 34:4102\u20134109","journal-title":"J Clin Oncol"},{"key":"1989_CR17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-016-0588-x","volume":"76","author":"L Festino","year":"2016","unstructured":"Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, Melero I, Ascierto PA (2016) Cancer treatment with anti-PD-1\/PD-L1 agents: Is PD-L1 expression a biomarker for patient selection? Drugs 76:925\u2013945","journal-title":"Drugs"},{"key":"1989_CR18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","volume":"28","author":"J Madore","year":"2015","unstructured":"Madore J, Vilain RE, Menzies AM et al (2015) PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials. Pigment Cell. Melanoma Res 28:245\u2013253","journal-title":"Melanoma Res"},{"key":"1989_CR19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2015.467","volume":"114","author":"S Diem","year":"2016","unstructured":"Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, Gore M, Larkin J (2016) Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 114:256\u2013261","journal-title":"Br J Cancer"},{"key":"1989_CR20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0127","author":"B Weide","year":"2016","unstructured":"Weide B, Martens A, Hassel JC et al (2016) Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. doi: 10.1158\/1078-0432.CCR-16-0127","journal-title":"Clin Cancer Res"},{"key":"1989_CR21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:45\u201351","journal-title":"JAMA Dermatol"},{"key":"1989_CR22","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S (2015) Pembrolizumabcutaneous adverse events and their association with disease progression. JAMA Dermatol 151:1206\u20131212","journal-title":"JAMA Dermatol"},{"key":"1989_CR23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/annonc\/mdw016","volume":"27","author":"PFC Ferrucci","year":"2016","unstructured":"Ferrucci PF, Ascierto PA, Pigozzo J et al (2016) Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 27:732\u2013738","journal-title":"Ann Oncol"},{"key":"1989_CR24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E et al (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13:473\u2013486","journal-title":"Nat Rev Clin Oncol"},{"key":"1989_CR25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/CMR.0000000000000256","volume":"26","author":"X Wen","year":"2016","unstructured":"Wen X, Wang Y, Ding Y, Li D, Li J, Guo Y, Peng R, Zhao J, Zhang X, Zhang XS (2016) Safety of immune checkpoint inhibitors in Chinese patients with melanoma. Melanoma Res 26:284\u2013289","journal-title":"Melanoma Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-1989-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-1989-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-1989-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T17:28:27Z","timestamp":1569086907000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-1989-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["1989"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-1989-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,25]]}}}